lamivudine patent runs out 2010

http://en.wikipedia.org/wiki/Lamivudine

The best selling NRTI for many years, otherwise known as 3TC, is the comparitor in the ATC trials. It's patent runs out in 2010. It has given GSK many billions of dollars in sales for many years and is the cornerstone of many HAART regimes.

Will they be looking for a new NRTI to replace it? Just imagine that for a moment, and let the implications sink in.